Mohamed N. Sharafeldin

Mohamed N. Sharafeldin

Auto-generated profile, based on publicly available information

Mohamed N. Sharafeldin

Nanomedicine Lab, Center of Materials Science (CMS), Zewail City of Science and Technology, 6Th of October, Egypt

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2025 in Discover Nano
Verified
Journal Article
Open access
PDF file
MTMuhammad Talaat
Muhammad Talaat
HHHamsa Hassan
Hamsa Hassan
EMEthar Ahmed Mosilhy
Ethar Ahmed Mosilhy
NTNouran A. Taha
Nouran A. Taha
MEMohamed Elsaid
Mohamed Elsaid
MSMahmoud E. Soliman
Mahmoud E. Soliman
Antioxidants showed usefulness in treating or preventing neurodegenerative diseases (NDDs). However, antioxidants have limited bioavailability owing to the

13 August 2024
Verified
Book Chapter
Closed access
PDF file
KKKhaled M. Kotb
Khaled M. Kotb
MSMohamed N. Sharafeldin
Mohamed N. Sharafeldin
HHHamsa Hassan
Hamsa Hassan
ABAchouak Boutalbi
Achouak Boutalbi
AYAhmed Yahya
Ahmed Yahya
ASAmgad E. Salem
Amgad E. Salem
Neurodegenerative diseases include diverse conditions (e.g., Parkinson’s disease and Alzheimer’s disease) in which ongoing loss of neurons and glial cells is implicated. They lead to impaired motor and cognitive functions. Although there is an advancement in therapeutic options impacting the pathogenetic mechanisms of the disease, the BBB exerts a physiological barrier that hinders their access to the brain. Thereby, novel drug delivery approaches have been considered to enhance CNS targeting and bioavailability. There is increasing evidence that lipid-based nanocarriers (e.g., liposomes) may improve brain targeting and ease BBB transportation. Nevertheless, no authorized nanoformula targets the CNS till now. We aim to summarize the relevant literature about the different types of lipid-based nanocarriers and the findings of the preclinical and clinical trials conducted so far through systematic and manual searches in PubMed. Hence, it may be inspiring to translate this approach into clinical practice and benefit from their pharmacokinetic characteristics. Moreover, we attempt to highlight the challenges and future outlooks for their implementation in clinical practice. Overall, it is still early for these applications to be translated into clinical practice due to several reasons, including safety concerns; the lack of simple formulas that can be eligible and allow affordable, large-scale production; and the absence of reliable, high-quality, and strong evidence. We suggest that there is a necessity for appropriately designed controlled trials and standardized analytical methods. <!----> <!----> <!----> <!---->